Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for VYNE Therapeutics Inc. (VYNE) provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. These documents include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, which together outline VYNE’s financial condition, risk factors, clinical programs and material corporate events.
Through its filings, VYNE describes its focus on developing differentiated BET inhibitor therapies for chronic inflammatory and immune-mediated conditions, including programs such as the oral BD2-selective BET inhibitor VYN202 and the topical pan-BD BET inhibitor repibresib gel. Periodic reports discuss research and development spending, general and administrative expenses, royalty revenue from its agreement with LEO Pharma A/S for Finacea® foam, and cash runway expectations under various operating assumptions.
Current reports on Form 8-K highlight specific developments that may be important to investors. Examples include disclosures of quarterly and annual financial results, clinical trial updates that are furnished as exhibits, and governance changes such as director resignations. A notable Form 8-K filed on December 17, 2025 describes VYNE’s entry into an Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc. and a merger subsidiary. That filing summarizes the structure of the all-stock merger, the expected pro forma ownership split, planned stockholder approvals, and conditions to closing, as well as related financing arrangements and support agreements.
Other 8-K filings detail the company’s annual meeting voting results and confirm its continued listing of common stock on The Nasdaq Stock Market LLC under the symbol VYNE. Together, these filings allow readers to review how VYNE reports material events, manages its capital structure and describes its strategic review and merger plans.
On this page, AI-powered tools can help interpret complex sections of lengthy filings by highlighting key points, summarizing risk factor themes and explaining the implications of items such as merger agreements, clinical program disclosures and changes in governance. Users can quickly locate information about VYNE’s quarterly performance in Forms 10-Q, its annual overview and risk disclosures in Form 10-K, and specific events reported on Forms 8-K, while using AI-generated summaries as a guide to the underlying regulatory text.